GPCR - CIK 0001888886
The table below shows Structure Therapeutics Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $66.51M | $58.99M | $54.71M | $42.87M | $32.60M | $22.05M |
| SG&A |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $22.87M |
| $14.80M |
| $15.74M |
| $13.44M |
| $13.24M |
| $11.27M |
| Operating income | -$89.38M | -$73.79M | -$70.45M | -$56.31M | -$45.84M | -$33.32M |
| Income tax | $190.00K | $108.00K | $139.00K | $98.00K | $92.00K | $53.00K |
| Net income | -$75.97M | -$65.71M | -$61.66M | -$46.83M | -$33.98M | -$26.03M |
| EPS (diluted) | -$0.35 | -$0.37 | - | -$0.27 | -$0.20 | -$0.18 |